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Abstract: Cancer stem cells (CSCs) account for tumor initiation, invasiveness, metastasis,
and recurrence in a broad range of human cancers. Although being a key player in cancer development
and progression by stimulating proliferation and metastasis and preventing apoptosis, the role of the
transcription factor NF-κB in cancer stem cells is still underestimated. In the present review, we will
evaluate the role of NF-κB in CSCs of glioblastoma multiforme, ovarian cancer, multiple myeloma,
lung cancer, colon cancer, prostate cancer, as well as cancer of the bone. Next to summarizing current
knowledge regarding the presence and contribution of CSCs to the respective types of cancer, we
will emphasize NF-κB-mediated signaling pathways directly involved in maintaining characteristics
of cancer stem cells associated to tumor progression. Here, we will also focus on the status of
NF-κB-activity predominantly in CSC populations and the tumor mass. Genetic alterations leading
to NF-κB activity in glioblastoma, ependymoma, and multiple myeloma will be discussed.
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1. Introduction
Cancer stem cells, also called neoplastic stem cells or cancer initiating cells, were discovered
by transplantation in immunocompromised mice. Only a small fraction of all dissociated cells was
propagated in the nude mouse model (1/250,000) [1]. Since one cell with markers for stem cells such as
CD34 for leukemia or CD133 for solid cancers could initiate cancer growth, the concept of cancer stem
cells (CSC) was born. Characteristics of CSCs are self-renewal, differentiation in other more mature cell
types, presumable from different germ layers, and tumor initiation in suitable mouse model. In vitro
propagation as spheres, dye exclusion and resistance to chemotherapeutics, and lack of MHC class I
expression can be used for characterization [2–4].
Cancer stem cells manifest the capacity of self-renewal, DNA repair, persisting in the G1 or G0
cell cycle phases as inactive dormant cells, and asymmetric cell division. Interestingly, especially
asymmetric cell division is discussed for being a hallmark of CSCs [5,6]. For instance, Takeda and
colleagues recently reported 90% of Sox2-positive colon cancer stem cells to undergo asymmetric cell
division. In this line, breast cancer stem cells express the receptor Notch, which could be stimulated by
NF-κB-mediated expression of its ligand JAG1 on non-cancer stem cells. Thus, proliferation of CSCs
can be triggered by an NF-κB-dependent mechanism [7]. As a further major hallmark, CSCs do not
undergo apoptosis and they manifest overexpression of ABC genes, which is linked to their resistance
to cytostatic drugs. Control of their self-replacement is associated in principle with numerous signaling
pathways, including Notch, Sonic hedgehog (Shh), and wingless-type (Wnt). Cancer stem cells can
be identified and isolated due to their specific markers, such as CD44, CD133 (prominin-1, see also
Figure 3B), CD117 (c-Kit), ALDH1 (aldehyde dehydrogenase), and OCT3/4 (POU5F1), the transcription
factor of the POU (Pit-Oct-Unc) family. In addition to these commonly accepted marker panels for CSC
identification and isolation, increasing evidences suggest intracellular signaling pathways mediated by
the transcription factor named “nuclear factor kappa-light-chain enhancer of activated B-cells” (NF-κB)
to be of particular importance for CSC characteristics and functionality.
NF-κB is ubiquitously expressed and mediates a broad range of cellular processes ranging
from apoptosis, cell growth, inflammation, memory, and learning to immunity [8,9]. The NF-κB
family is characterized by a conserved n-terminal REL homology domain (RHD) being crucial for
DNA-binding and dimerization of NF-κB family members. These family members particularly
include the five subunits of NF-κB, namely RELA (p65), RELB, c-REL, p50 and p52, and the NF-κB.
The NF-κB subunits RELA, RELB, and c-REL additionally comprise a C-terminal transactivation
domain (TAD) [10]. As schematically depicted in Figure 1, inhibitors of κB (IκBs) mask the NLS
(nuclear localization signal within the RHD) of NF-κB p50/p65 dimers, thereby preventing their
nuclear translocation. Binding of ligands to their respective receptors (such as CD40) results in
phosphorylation of the IκB kinase (IKK) complex (IKKγ/IKKα/IKKβ) in a C-IAP-, TRAF2/3-, and NIK
(NF-κB-inducing kinase)-dependent manner. Phosphorylated IKKs in turn phosphorylate IκBα
resulting in its proteasome-mediated degradation and demasking of the NLS within the p50/p65 NF-κB
dimer. The NF-κB dimer is subsequently translocated into the nucleus and binds to specific target
sites, thus enabling target gene expression [9,10]. Next to this canonical NF-κB signaling cascade,
non-canonical NF-κB signaling is mediated by phosphorylation of IKKs via NIK, in turn leading to
phosphorylation of p100 and its proteasomal processing to p52 [11] (see also Figure 1 for overview).
Subsequent nuclear translocation of the p52/RELB NF-kB dimer is followed by binding to selective kB
sites and activation of specific target genes. Various aspects of cancerogenesis and cancer progression
are directly associated to deregulation of canonical and non-canonical NF-kB signaling pathways due to
its various cellular functions and target genes [12–16]. In particular, canonical NF-kB signaling mediates
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vital tumor-promoting mechanisms like stimulation of cell proliferation and prevention of apoptosis,
epithelial-to-mesenchymal transition (EMT), angiogenesis, invasiveness, as well as metastasis. As a
driver of such crucial mechanisms inducing and propagating tumor growth, NF-κB was shown to
be constitutively active in a broad range of cancers from various organs. Constitutive activity of
NF-κB subunits in turn arises from a prolonged chronic inflammatory microenvironment or by various
oncogenic mutations [12,17,18]. In chronic inflammation, accumulation of proinflammatory cytokines
caused by increased activity of NF-κB was shown to promote a protumorigenic microenvironment in
colon cancer [19]. However, NF-κB has also been described to have anti-inflammatory roles with direct
effects on tumor formation and therapy resistance (reviewed in [20]). For instance, overexpression of
the NF-κB p50 homodimer in tumor-associated M1 macrophages was reported to inhibit inflammatory
and antitumor responses in murine fibrosarcoma. Defective responsiveness of tumor-associated
macrophages to M1 activation signals in human ovarian carcinoma was also associated with activation
of the NF-κB p50 homodimer [21], suggesting a context-dependent role of NF-κB-activity at least in
cancers related to chronic inflammation.
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ovari n cancers could show C L5-dependent activati 65- ediating MMP9-expression,
migration, angiogenesi , and epithelial differentiatio of S [ (l . Canonical and
non-canonical NF-κB signaling i CSCs from multiple mye oma including ommonly known mutations,
which generate constitutive NF-κB-activity. Mutations are shown i boxe (right upper panel, modified
from [23]). Development of plasma cells from pre-B cells in the bone marrow (right lower panel).
Note that most authors think that NF-κB mutations are acquired during naive B cell to plasma cell
differentiation, although high levels of pre-B cells in multiple myeloma patients might hint to some
mutations already in present in the bone marrow.
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In line with its essential role in cancer development and progression, increasing evidence suggests
NF-κB to be pivotal in generation of CSCs and maintaining their functionality. With regards to
maintenance of self-renewal of CSCs, Iliopoulos and coworkers discovered an epigenetic switch in
mammospheres induced by overexpression of the SRC oncogene as a model of CSCs development in
breast cancer [24]. In particular, a short period (24 h) of induction by SRC was sufficient to change gene
expression in a manner that NF-κB and STAT3 signaling became dominant (see Figure 2). Furthermore,
expression of transcription factor LIN28 was induced, which is a repressor of LET7 microRNA, thus
releasing the repression of IL6 protein expression. Recent findings elaborated these observations to a
more general model for the regulation of an inflammatory regulatory network in many human cancers
(see Figure 2). This network involves three major inflammatory pathways: NF-kB, which can be
activated by members of the TNF superfamily (TNFSF) and IL1, the transcription factor AP1 (JUN/FOS),
and STAT3. All three transcription factors are activated by transmembrane receptors, which impinge
on kinases (IKKs for NF-KB, JNK for AP1, and JAK for STAT3, see Figure 2 and [25]).
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a high correlation of pro-inflammatory signaling and tumor progression. For further details, see
respective text (modified from [25]).
In line with the depicted fee -back loop of the repression of miRNA LET7 by embryonic
transcription factor LIN28B in cancer ste cells (Figure 2), Markopoulos and coworkers recently
reviewed more than 150 miRNAs acting on NF-κB in cancer [26]. Accordingly, we could previously
show that NF-κB RelA protein is repressed by microRNAs in embryonic stem cells and that this
repression is released during neuronal differentiation [27,28].
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Among the broad range of NF-κB target genes and associated pathways, epithelial-to-mesenchymal
transition (EMT) is one of the most prominent ones in regulating CSC-functionality [29,30]. Here,
NF-κB regulates transcription of SNAIL, Slug, ZEB1, ZEB2, and Twist, which repress the epithelial
phenotype and are directly associated to cancer invasiveness and aggressiveness as well as poor patient
survival [30]. Regarding the induction of mesenchymal markers, NF-κB also regulates expression of
Matrix metalloprotease (MMP) 2 and MMP9, as well as Vimentin. Particularly Vimentin-positive CSCs
seem to represent the end stage progression of EMT, concomitant with a completely dedifferentiated
state, which is highly proliferative and invasive [30]. In line with these observations, EMT was shown
to generate cells with properties of stem cells from human mammary epithelial cells. Stem-like cells
showed increased expression of stem cell markers, sphere formation ability, and more efficient capability
for tumor formation [31]. Accordingly, blocking of NF-kappaB activity was reported to prevent EMT
and metastatic potential of Ras-transformed mammary epithelial cells, likewise suggesting NF-κB
activity to be critical for the cooperation of Ras- and TGF-beta-dependent signaling pathways [32].
Here, we limited ourselves to the KEGG pathway “NF-kappa B signaling pathway—Homo
sapiens (human)” as depicted in [33,34]. Even here, we simplified the canonical and non-canonical
pathways for the sake of eligibility. It might be clear that NF-κB is cross-coupled to several other
pathways. For example, there is a negative regulation of NF-κB activity by glucocorticoid receptor
signaling [35]. Another developmentally important pathway involving secreted protein ligands of the
Wnt (wingless family) shows both negative and positive action on the NF-κB pathway (as reviewed
in [36]). Wnt/β-catenin pathway components could regulate responses via the interaction with the NF-κB
pathway. In turn, NF-κB could influence the activity of Wnt/β-catenin signaling pathway. Specifically,
overexpression of beta catenin in breast and colon cancer could inhibit NF-κB activity by physical
interaction, but there are reports on positive regulation [37]. Furthermore, in transformed mammary
epithelial cells, TGF-β and Wnt signaling synergize to induce activation of the epithelial–mesenchymal
transition (EMT) program, and function in an autocrine fashion to maintain the resulting stem-cell
state [38]. The complex cross-talk between signaling pathways of Wnt, Notch, Hippo, Hedgehog
(Hh), mitogen-activated protein (MAP), kinase, phosphoinositide 3-kinase (PI3K)-Akt, and the nuclear
NF-κB has been covered in a recent review [39].
Emphasizing the pivotal roles of NF-κB in CSCs, the present review will focus on discussing
commonly known as well as recently described CSC populations in a broad range of organ specific
cancers (see Figure 3A for overview), starting with glioblastoma multiforme as the most frequent
cancer type in brain. We focus on the contribution of distinct CSC-populations to cancer progression,
thereby emphasizing the role of NF-κB as a crucial mediator for biology and function of CSCs.
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in the left and right image. Note the nest-like appearance of CD 133 positive cancer stem cells within
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2. Cancer Stem Cells in Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most co mon primary brain cancer and particularly
characterized by a notable cellular heterogeneity and aggressiveness as well as extensive invasiveness
into neighboring brain tissue. The greatest problem is its inevitable recurrence. GBM patients have an
average survival of less than two years [40–42]. In selected cases with a molecularly characterized
tumor subtype, a combination therapy with lomustine and temozolomide may increase survival time
to four years [43].
GBM contain a variety of poorly differentiated neural cells. Three major cell types are mostly
recognized within GBM. This includes a population of relatively rare cancer stem cells, which are able
to self-renew and repopulate the cancer. Next to cancer stem cells, quiescent cells, having exited the
cell cycle, are likewise present in GBM. These quiescent GBM cells are characterized by a slow cellular
turnover and no persistent self-renewal capacity. Both GBM CSCs and quiescent cells have the capability
to give rise to the third pool of GBM cell types, the differentiated GBM cells. Differentiated GBM
cells, which also include different stages of incomplete differentiation and respective progeny without
tumor-propagating capacity, are the most prevalent cell pool in GBM and show mitotic activity.
Stem-like cells can be found in the tumor infiltration zone (i.e., beyond the margins of the surgical
resection), and therefore contribute prominently to tumor recurrence [44]. The differentiated GBM cell
pool is considered as the main contributor to GBM tumor mass development [45–50].
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Activation of NF-κB in glioblastoma was subject of a recent review [51]. Unregulated constitutive
NF-κB activity is commonly observed in GBM and was proposed to be caused by several mechanisms.
For instance, receptor tyrosine kinases like epidermal growth factor receptor (EGFR) or platelet derived
growth factor receptor (PDGFR)are often constitutively activated in GBM. Involving both protein
kinase B/AKT (AKT)-dependent and -independent pathways, activation of EGFR and PDGFR have
been linked to NF-κB activation. EGFR gene amplification and overexpression of a constitutively active
variant are considered molecular hallmarks of GBM, and have been explored as potential therapeutic
targets [52]. In addition, there is a cellular crosstalk mediated by IL-6 and NF-κB, which leads to
attenuation of EGFR tyrosine kinase inhibitors (TKEs) [53]. Targeting the NF-κB target gene IL-6 was
also demonstrated to directly reduce survival of CSCs in GBM concomitant with decreased tumor
growth [54]. Pyruvate kinase M2 (PKM2), a member of the enzyme family regulating the rate-limiting
step of glycolysis, is overexpressed in numerous cancers and could be regulated in glioblastoma by
NF-kB [51,55]. In addition, A20 (TNFAIP3), an NF-kB target gene and regulator of cell survival, was
reported to be overexpressed in CSCs from GBM with elevated levels of A20 in GSCs contributing to
apoptotic resistance [56]. Interestingly, a recent genetic analysis showed deletion of the IκBα (NFKBIA)
gene in up to 24% of glioblastoma patients [57].
Happold and coworkers analyzed glioblastoma cancer stem cells and described NF-κB as a
positive regulator of MGMT (O6-methylguanine DNA methyltransferase) mediated by NF-κB p65 [58].
Of note, MGMT promoter hypermethylation has proven an important predictive biomarker for benefit
from alkylating chemotherapy as well as powerful prognostic factor [59,60]. This has resulted in
attempts at therapeutic stratification of glioblastoma based on MGMT methylation status [43,61].
We could recently show that rat neurosphere cultures could be transformed by forced culture to
a growth factor-independent characterized by constitutively activated NF-κB and production of
VEGF [62]. In line with these findings, angiogenesis mediated by VEGF could be also regulated by
NF-kB in glioblastoma [63]. Here, glioblastoma stem cells were recently shown to secrete VEGF-A
in extracellular vesicles [64]. VEGF receptor inhibition as a therapeutic concept for glioblastoma has
attracted much attention in recent years. The VEGF inhibitor bevacizumab has won FDA approval
and is in widespread use in the US. Others are more critical, and several large prospective trials have
failed to convincingly demonstrate a survival benefit both in primary as well as patients with recurrent
glioblastoma. Many feel that bevacizumab reduces peritumoral edema, and has only very limited
tumoricidal activity, at the least [61,65].
CSCs from glioblastoma seem to be highly resistant to the treatment with Smac mimetics, which are
small molecule drugs inhibiting members of IAP (inhibitor of apoptosis) proteins. In CSCs from
glioblastomas, Smac mimetics trigger an adaptive response with increased expression of TNFα and
sustained activation of NF-κB and STA3 signaling [66]. The cross-talk between NF-κB and STAT3
drives tumor progression and promotes stemness characteristics of cancer in multiple malignancies
including gliomas [67]. Furthermore, glioma stem cells secrete Sema3C and coordinately express Plexin
A2/D1 receptors to activate Rac1/NF-κB signaling in an autocrine/paracrine loop to promote their
own survival [68]). Another source of NF-κB activation in GBM involves the TGF-β/TAK1 signaling
axis, which could activate both canonical and non-canonical NF-κB signaling [69]. Proneural (PN)
and mesenchymal (MES) glioma stem cells (GSCs) represent two mutually exclusive and biologically
distinct GSC subtypes. Recently, it was shown that mixed lineage kinase 4 (MLK4) is overexpressed in
MES but not proneural PNGSCs. Silencing MLK4 suppressed self-renewal, motility, tumorigenesis,
and radio-resistance of MES. MLK4 bound and phosphorylated the NF-κB regulator IKKα, leading to
activation of NF-κB signaling in MES [70].
A novel NF-κB target gene is the telomerase reverse transcriptase (TERT). TERT can also activate
NF-κB p65 (RelA), facilitating a feed forward loop (as reviewed in [14]), which enables increased
binding to recently described TERT promotor polymorphism. TERT promoter mutations are thought
to characterize primary as opposed to secondary GBM (i.e., GBM developing from a preexistent
lower-grade glioma), and may play a role as a prognostic factor [71,72]. In line with these findings,
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TERT function was also shown to induce CSC characteristics in glioma cells via EGFR expression [73].
In summary, IKK/NF-κB signaling directly contributes to glioblastoma stem cell maintenance, as recently
demonstrated by Rinkenbaugh and coworkers [69].
3. Cancer Stem Cells in Pediatric Cancer
Only around 0.5% of all newly diagnosed cases of cancer in Germany concern children or
adolescents. This means that the overall incidence for cancer in this age group is around 14 of
100,000. Therefore, cancer in children may be appraised as a rare disease. Still, cancer is the second
most frequent cause of death in patients beyond the first year of life after accidents. Since 1980, in
Germany, all patients less than 18 years with cancer are enrolled in a specific register, so that we
have detailed knowledge about entities, mortality rates, and treatment efficacy. Overall incidences in
the last decades are not growing, although the number of patients with brain tumors has increased,
most likely due to a better diagnosis and reporting system. By far the most frequent types of
cancer in childhood contain lymphoblastic leukemia (nearly 30%), followed by astrocytoma (10%),
neuroblastoma (8%), nephroblastoma and Non-Hodgkin-Lymphoma (6% each), non-lymphoblastic
leukemia, and neuro-endocrine tumors (4% each) [74].
With 16,050 deaths per year, brain tumors were reported to be the leading cause of cancer death in
children [75]. Here, glioblastoma multiforme (GBM; World Health Organization grade IV astrocytoma)
is ranging among the most malignant and aggressive forms of brain tumors [76]. Opposite to the
overall better survival rates of children with cancer, GBM survival rates have remained low for the
last 50 years, with a median survival time of 12–18 months [77]. This explains why there is a big
unmet need for more effective and individualized therapies that should be based upon the specific
pathophysiology of the tumors and their microenvironment [78].
In pediatric tumors, acute myeloid leukemia stem cells were the first CSCs being identified [79] via
expression of the hematopoietic stem cell marker CD34, while lacking the lymphocyte differentiation
marker CD38 [80]. This initial report was followed by the observation of CSCs in a broad range
of pediatric brain tumors, including medulloblastomas [3] and high-grade gliomas (HGGs) [81].
The technical proof for CSCs in pediatric brain tumors was similar as in adults: CSCs were isolated from
bulk tumors using stem cell markers, then demonstrated their capacity for self-renewal, differentiation,
and recapitulation of the original tumor [82].
CSCs in pediatric brain tumors express similar CSC markers as in adults (including CD133,
SOX2, musashi-1, BMI1), but also show elevated expression of maternal embryonic leucine zipper
kinase and phosphoserine phosphatase [83]. Moreover, epigenetic regulation plays a bigger role
in pediatric than in adult brain tumors, since developing a brain tumor within the first two years
of life is more likely to be the result of cancerogenic transformation caused by genetic and/or an
epigenetic variation. On the contrary, an adult brain is rather long-term exposed to mutagenic
transformation events occurring in oncogenes or tumor suppressor genes [84]. This diversity between
childhood and adult brain tumors highlight that the CSC populations in these tumors most likely
represent distinct targets for personalized therapeutic intervention. A role for NF-κB RELA in pediatric
neuro-oncology is manifested by the RELA fusions in 70% of supratentorial ependymoma [85,86].
But only C11orf95–RELA fusions led to the development of ependymoma in a mouse model, whereas
overexpression of C11orf95, or RELA or other fusions did not drive tumorigenesis in this model [87].
In particular, C11orf95–RELA fusion proteins were shown to activate NF-κB target genes in neural
stem cells, leading to their transformation and initiation of tumor growth [85]. In Wistar rats, NF-κB is
developmentally regulated during cerebellum development with high constitutive activity at p5 in
neuronal stem cells, which drops dramatically during later life, suggesting a potential correlation with
the effect of RELA fusion [88].
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4. Ovarian Cancer and Cancer Stem Cells
Each year, 240,000 women are diagnosed with ovarian cancer worldwide and 150,000 die of it.
Further, 47% of all deaths from cancer of the female genital tract occur in women with ovarian cancer,
although only 23% of gynecologic cancers are ovarian in origin. Epithelial ovarian cancer is responsible
for 5% of all cancer-related deaths in women [89]. The incidence rate is highest in high-income countries
and increases with age. The largest number of patients with epithelial ovarian cancer in high-income
countries is found at 60–64 years of age; in low-income countries, the median age is about one decade
earlier [90]. Risk factors include reproductive factors. Women who have never given birth are twice as
likely to develop ovarian cancer. Early menopause and the use of oral contraceptives are associated
with a lower risk for the disease [91].
Notably, germline mutations in BRCA1/2 were observed in at least 15% of women with high grade
non-mucinous ovarian cancers, despite that 40% of these women did not have a family history of breast
or ovarian cancer [92]. The risk for developing ovarian, tubal, or peritoneal cancer for women with
BRCA1 deleterious mutations is around 20–50% and 10–20% with a BRCA2 mutation. These cancers
occur at an earlier age with a median age of diagnosis in the mid-40s [93]. Notably, BRCA1 was shown
to associate constitutively with NF-κB p65, while p50 associated only with BRCA1 upon DNA damage
treatment. Harte and coworkers thus described a functional interdependence between BRCA1 and
NF-κB, which is required for BRCA1-mediated resistance to DNA damage [94]. In addition, NF-κB was
demonstrated to directly regulate DNA double-strand break repair in a BRCA2-dependent manner
as well as via interaction with CtIP-BRCA1 complexes and promotion of BRCA1 stabilization [95].
There are no effective screening methods that reduce the mortality of ovarian cancer [96]. The prognosis
of ovarian cancer is dependent on stage of the cancer, histologic type and grade, and maximum
diameter of residual disease after cytoreductive surgery [97].
Surgery includes the staging laparotomy and debulking surgery at the same time: All peritoneal
surfaces are evaluated, peritoneal fluid or ascites is retrieved, (at least) infracolic omentectomy and
lymphadenectomy of the pelvic and para-aortal lymph nodes, total hysterectomy, and bilateral
salpingo-oophorectomy is performed. For mucinous tumors, appendectomy is mandatory.
Optimal cytoreduction may necessitate bowel resection and resection of other organs or structures [98].
In selected patients with cytologically proven advanced disease, neoadjuvant chemotherapy may be
given initially, followed by interval debulking surgery, and additional chemotherapy [99]. Patients who
have had primary cytoreductive surgery for advanced ovarian cancer should receive platinum-based
combination chemotherapy following surgery [100]. Bevacizumab, an antibody against VEGF-A, may
be added to this regimen [101].
After cisplatin treatment, the dormant cells of human ovarian cancer displayed an augmented
expression of cells with Oct-4, nestin, CD-117, and CD44 markers, proving the resistance of
this stem cell fraction to cisplatin [102]. Thus, additional treatments with drugs more specific to
CSC such as Salinomycin and/or Metformin might be considered [103]. In this line, it could be
shown that Salinomycin inhibits NF-κB and induces apoptosis in cisplatin resistant ovarian cancer
cells [104]. Furthermore, safety of treatment with allogenic in vitro cultured NK cells delivered into the
intraperitoneal space by laparoscopy was studied [105]. It was shown, using CSC from ovarian cancers
by magnetic sorting (anti CD133), that NF-κB-mediated migration is activated by an autocrinous loop
of CCL5 to RelA [22] (Figure 1). Interestingly, CSCs can differentiate into endothelial cells under the
influence of CCL5 [106]. Both RelA and RelB support ovarian cancer growth in a mouse model [107].
Blocking of classical NF-κB pathway results in reduction of CD44+ CSCs in ovarian cancer [108].
5. The Role of Cancer Stem Cells in Multiple Myeloma
Multiple myeloma is a monoclonal B-Cell neoplasia, characterized by proliferation of plasma
cells and production of complete or incomplete antibodies (see Figure 1). The proliferation of
plasma cells might lead to osteolytic lesions, renal insufficiency, hypercalcemia, and hematopoietic
insufficiency. The incidence in Germany is about 6500 newly diagnosed diseases per year (http:
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//gekid.de/download/1112/). Precursor stages of multiple myeloma could be MGUS (monoclonal
gammopathy of unclear significancy) and smoldering myeloma. In contrast to a merely specific
disease, multiple myeloma depicts genetic heterogeneity. In about 40% of cases, different kinds of
trisomy are found. A chromosome 14 translocation is frequently observed, particularly containing the
immunoglobulin heavy-chain locus like t(11;14), t(4;14), t(14;16), t(6;14), t(14;20). These chromosomal
aberrations are found in MGUS also [109]. Furthermore, it can be discussed, that secondary aberrations
like RAS mutations and translocations involving MYK could influence the course of disease and
prognosis of myeloma [110]. There are different hypotheses for the genesis of multiple myeloma.
The classic view on the evolution of multiple myeloma focuses on mature plasma cells in the bone
marrow, where oncogenic mutations transformations took place. In summary, multiple myeloma
was mostly described as a tumor arisen from transformed plasma cells [23]. Another emerging
concept focuses the myeloma stem cell (MMSC), which is able to self-renew and differentiate into
myeloma plasma cells. The MMSC is therefore categorized as a progenitor cell of the plasma cell.
These cells are summarized as cancer initiating cells or cancer stem cells. A landmark study by Bonnet
and Dick described a hierarchy of cells within human acute myeloid leukemia [80]. By transfer in
immunocompromised mice, they identified a leukemia stem cell that was almost exclusively CD34+;
CD38−. Most interestingly, in multiple myeloma patients, peripheral blood lymphocytes express
high levels of CD34, with levels up to 37% in comparison to 5% in normal controls. Up to 98%
of these CD34+ cells are positive to CD19 [111]. Taken together these data suggest the presence
of malignant MMSC which could give rise to metastasis. Based on these findings, a multination
consortium of clinicians suggested a selected sampling of biomaterial of different clinical stages and
disease spectrum [112]. We plan to analyze the contribution of NF-κB to MMSC. In this line, most
NF-kB activating mutations were attributed to mutations acquired by a stromal independent multiple
myeloma cell (see [23] for discussion). Notably, canonical NF-κB signaling was already observed
to be required for persistence functionality of mature B cells [113] and is a hallmark of various B
cell lymphomas [114]. NF-κB cRel is further known as a key regulator of B-cell proliferation and is
frequently amplified in B-cell lymphoma [115], but was also described to have a tumor suppressor role
in lymphoma development [116]. In Figure 1, we summarize hypotheses for the generation of multiple
myeloma and the activation of NF-κB.
6. Lung Cancer and Cancer Stem Cells
Lung cancer is the second most common malignancy in males after prostatic cancer and,
surprisingly, it is now the second most common malignancy in females after breast cancer. According to
its histological differentiation, it is classified into two main categories; small-cell lung cancer (SCLC)
(less frequent form of the disease with an incidence of about 20% of all lung cancers) and the
non-small-cell lung cancer (NSCLC) category (most frequent form with an incidence of about 80%).
Treatment depends on the stage of the disease. In early stages (I and II), surgery, if possible, is the
“gold standard” treatment. In higher stages (IIIA and IIIB), neoadjuvant (induction, preoperative)
chemotherapy/radio-chemotherapy is an established way for better outcomes. In case of advanced
stages especially with multiple metastases, palliative chemotherapy is the main strategy. In the last
few years, target therapy or immune therapy has been gaining popularity but is still in its primitive
age. In many cases, adjuvant therapy is needed after surgery. Nevertheless, the overall prognosis
of NSCLC is bad, with a five-year survival rate as low as 15% [117]. Therefore, search of additional
biomarkers for the development of novel treatments is mandatory. In mice, the bronchioalveolar
duct junction of the adult mouse lung was suggested to harbor a stem cell population, which can be
activated by K-Ras and gives rise to adenocarcinomas [118,119]. Next to bronchoalveolar stem cells,
alveolar type II progenitor cells, which are Clara cells in the terminal bronchioles, were reported to
directly contribute to K-Ras-induced lung hyperplasia [120,121]. K-Ras-induced tumorigenesis via
type II progenitor cells in the mice lung was further shown to depend on Sox2 expression in turn
affecting Notch signaling [122].
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NF-κB signaling is involved in multiple steps of carcinogenesis of lung cells and mediates resistance
of lung cancer cells to radio- and chemotherapy [123]. In addition, NF-κB provides one important
linkage between the pathogenesis of pulmonary inflammation and cancer [124]. In this line, a recent
meta-analysis [125] showed that NF-κB-positive lung cancer cells (analyzed by immunohistochemistry)
are highly significantly correlated with shorter overall survival time. This might be true for both
canonical and non-canonical NF-κB signaling pathways [126,127]. Not much information about NF-κB
in lung CSCs is available. Only recently, CSCs were generated from the lung cancer cell lines A547 and
H2170. In this model, stemness markers such as tumor sphere growth, OCT4, SOX2 and NANOG gene
expression, and EMT markers were reduced after pharmacological NF-κB inhibition [128].
7. Cancer Stem Cells in Colon Cancer
With 450,000 new cases of colorectal cancer (CRC) in 2008 and 232,000 deaths, CRC represents the
second most important cause of cancer death in Europe according to the WHO [129]. Environmental,
gender, and genetic factors as well as inflammatory bowel disease like ulcerative colitis and specific
prevalence of fusobacterium and other bacterial species in the microbiome of the gut are risk factors
for CRC [130–133]. The aim of preoperative neoadjuvant chemo-radiation therapy is to reach
downstaging/downsizing of the disease followed by surgery with improved survival [134]. Surgery is
the only curative treatment modality for localized CRC. The onco-surgical approach consists of
resection of the colon or rectum bearing the carcinoma, en-bloc with the draining lymph node stations.
Radical lymphadenectomies, like total mesorectal excision in rectal and complete mesocolic excision in
right colon cancer, have been demonstrated to improve local recurrence and overall survival [135,136].
Latent micro-metastases present at the time of surgery are thought to account for recurrence following
curative colon resection. To increase the cure rate, the goal of postoperative (adjuvant) therapy is
to eradicate these micro-metastases. The benefits of adjuvant chemotherapy have been most clearly
demonstrated in stage III (node-positive) disease [137]. Significant progress in antibody-mediated
therapy (e.g., Cetuximab (Erbitux®), Bevacizumab (Avastin®), and Panitumumab (Vectibix®)) was
recently made [138]. There is a lot of information about normal tissue stem cells in the intestine and
CRC. Normal colon stem cells were reported to be Lrg5 positive and can built cryptvillus structures
in vivo [139]. But colon spheroid culture, which can initiate formation of xenografted colon carcinomas,
was heterogenous in the expression Lrg5 [140]. Interestingly, single clones of CD133+/CD24+ could
perform multilineage differentiation and could form tumors after xenotransplantation, albeit at a
frequency of about 20%. Noteworthy, in CRC CD24, low expression is correlated with lower survival,
whereas the opposite is true for breast cancer (the human protein atlas). In a mouse model of regulated
expression of stable beta catenin TNF-alpha-mediated NF-kB (RelA), activation was initiated in intestinal
crypt stem cells. This resulted in complete death of mice within 25 days after NF-κB activation. This was
correlated with a dedifferentiation of post-mitotic intestinal epithelial cells to tumor initiating stem cells.
Surprisingly, high expression of beta catenin seems to be favorable in CRC survival (the human protein
atlas) [141]. NF-κB-mediated EMT as promoter of motility and invasion of epithelial cancer cells is
also discussed to enable mesenchymal (stem cell) cell types out of the differentiated epithelium [142].
The axis of TGFβ/Snail with TNFα/NFκB pathways may facilitate the tumor–stroma interaction during
the EMT process in CRC worsening the prognosis [143]. NF-κB-mediated EMT-inducer SNAIL1
was demonstrated to be overexpressed already in precursor lesions of CRC [144]. NF-κB-mediated
EMT is negatively regulated by the scaffold protein DAB2IP. High expression of DAB2IP positively
correlated with five-year survival of CRC patients. Low expression of DAB2IP is correlated with
high CD133 expression and the formation or metastasis. Knockout of DAB2IP resulted in a profound
increase in nuclear RelA and CD44 [145]. Further, NF-kB demonstrated the capacity to modulate
tumor development in the scenario of inflammation. It was shown that inhibition of NF-κB in a
metastatic mouse model of CRC-lung-metastases blocks LPS-induced tumor proliferation, enhances
LPS-induced tumor apoptosis, and extends host survival [146]. Using a genetic model of intestinal
epithelial cell (IEC)-restricted constitutive Wnt-activation, which comprises the most common event
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in the initiation of colon cancer, it was demonstrated that NF-κB modulates Wnt signaling and that
IEC-specific ablation of RelA/p65 retards crypt stem cell expansion [141]. Pro-inflammatory PGE2
was demonstrated to induce CSC formation and expansion by activating NF-κB via EP4-PI3K and
EP4-MAPK pathways in vitro [147]. Inhibitors of NF-κB reduced PGE2-induced sphere formation
(an index of CSC expansion) and expansion of LS-174T and/or human primary CRC cells in that study.
In addition, knockdown experiments revealed that NF-κB was required for PGE2 induction of CSCs
and metastasis in mice. These data indicated that an inflammatory pathway, PGE2-NF-κB, mediates
the effects of chronic inflammation on CSC expansion.
8. Prostate Cancer and Cancer Stem Cells
Urological malignancies represent a large proportion of all cancers worldwide, mainly prostate,
renal cell, as well as bladder cancer [148]. Prostate cancer is the most common cancer among men
in industrialized countries as the United States, whereas it is the second most common cause of
cancer deaths (10%) in men [148]. All of these cancers are of epithelial origin. Acinar adenocarcinoma
of the prostate is an invasive carcinoma consisting of neoplastic epithelial cells without basal cells.
The neoplastic cells show a variety of histomorphological patterns: Glands, cords, single cells, and sheets
(see Figure 3B).
The tumors that are grossly recognizable are firm, tan or white, and macroscopically discrete.
The histological diagnosis is mainly based on the identification of invasive crowded small glands
with prominent nucleoli. Different histological variants and different patterns should be considered
when creating the diagnosis. Besides prostate cancer even bladder cancer and renal cell cancer are
more frequent in men than in female with 7% and 5% of all male cancer cases [148]. The cancers
mainly occur in the elderly from the age of 65 years and above. There is no screening tool for
bladder as well as renal cell cancer. In contrary, prostate cancer can be detected in an early stage
using prostate-specific-antigen-testing (PSA-testing) [149] and mortality is reduced when radical
prostatectomy is performed as curative therapy [150]. Lineage tracing in mice revealed a luminal
epithelial stem cell as origin of prostate cancer [151]. These cells express the homeobox-containing
transcription factor Nkx3.1 and are castration resistant. RNA and protein of NKX3-1 is highly enriched
in human prostate cancer (the human protein atlas). Human prostate tumor spheres (CSCs) express
NKX3-1 and show constitutive NF-κB signalling with increased IL-6 production [152]. Small molecules
inhibiting NF-κB significantly reduced tumor formation down to detection limits. Birnie and colleagues
identified genes with altered expression in prostate cancer stem cell population such as NFKB1 and
IL6 [153]. In this line, the NF-κB inhibitor parthenolide induced considerable amounts of apoptosis
in both CD133-positive CSC and normal progenitor cells. Surprisingly, TNF alpha did not lead to
significant nuclear translocation of p65 in sorted CD133-positve cells. More recently, it was shown that
prostate stem cell antigen (PSCA), which is highly expressed also in urothelial cancer, can induce IL-6
production via NF-κB. Expression of PSCA and IL-6 were significantly associated with poor survival
of patients with prostate cancer [154].
9. Cancer Stem Cells in Cancer of the Bone
Tumors and tumor-like lesions of the bone remain the rare tumors in humans (e.g., 1–2 primary
malignant bone tumors per 100,000 inhabitants/year). In Germany, 427 men and 352 women fell ill
in 2012, which corresponds to a proportion of 0.17/0.15% of all tumor diseases. In the age group of
children and adolescents (age <20 years), however, the incidence is 5.6% and 4.8%, respectively [155].
The prognosis in most malignant cases is poor.
Besides the more frequent entities (like chondroma, osteochondroma, fibrous metaphyseal defect,
solitary bone cyst), malignant tumors can be seldomly seen in daily clinical practice. Therefore,
experiences in diagnostic and especially in therapy are concentrated on specialized tumor centers.
However, due to the serious consequences of a misdiagnosis, basic knowledge has to be present in all
orthopedic and trauma departments to direct the patient to the interdisciplinary tumor specialists [156].
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The most common primary malignant bone tumor is the osteosarcoma. They appear in the
metaphysis of long bones especially in children and young adults. Although the etiology of most
sarcomas is not well known, some sarcomas are more likely to develop in certain patient populations,
in association with certain genetic, infectious, and therapeutic factors [155]. As a potential cellular
origin, a single cell located in the bone marrow is thought to give rise to a polyclonal, heterogeneous
tumor mass [157].
Actually, also in osteosarcoma, the model of cancer stem cells is under discussion.
Osteosarcoma CSCs have been demonstrated to be maintained by the stem cell transcription factor
Sox2 via inhibition of the Hippo pathway [158]. Although several methods have been developed
for identification of CSCs, none of these achieved to identify a pure CSC population or detect all
CSC sub-populations. Accordingly, is more likely to enrich the sample for (specific) CSCs due
to experimentally induced selection or, in some cases, environmental pressure [157]. Not much
information about NF-κB in osteosarcoma CSCs is available.
The main identified markers in osteosarcoma CSCs are the increased presence of ABC transporters
and elevated sphere formation ability accompanied by higher multidrug resistance (doxorubicin,
methotrexate, cisplatin) [157]. Another marker is the expression of aldehyde dehydrogenase.
Elevated expression of stemness genes like Nanog, Oct3/4, Stat3, and Sox2 were shown in CSCs
with high activity of ALDH. These CSCs likewise revealed an increased self-renewal ability as well as
a higher resistance to doxorubicin and cisplatin. The inhibition of ALDH activity using disulfiram
resulted in reduced cell proliferation [159]. Several cell surface markers have been identified on
osteosarcoma CDCs (CD133, CD117, Stro-1, and CD271) with influence on proliferation, sphere
formation, and drug resistance [157]. In this regard, the major goal of current osteosarcoma CSC
research is the identification of specific targets to effectively deplete CSCs during therapy [157].
10. Conclusions and Future Perspectives
In summary, we found compelling evidence for the pivotal role of NF-κB in organ-specific cancers.
Despite the discovery of cancer stem cells in 1994, the role of NF-κB in tumor-initiating cancer stem
cells is an emerging field. We suggest that further studies should be undertaken to carefully decipher
the specific roles of NF-κB subunits in cancer stem cells. Furthermore, these studies may be coupled
with state-of-the-art CRISPR/Cas9-mediated deletion/modification methods. In this line, we recently
developed tools for specific genetic engineering of NF-κB in tumor cells [160,161], which may be
applied for cancer stem cells in future studies. A common problem of cancer stem cells is their relative
resistance to common transfection methods (unpublished observations), which might be relieved by
the use of lentiviral transduction systems. For therapeutic intervention, cultured cancer stem cells
might be an ideal platform to test combination therapy, such as antibodies, cell-mediated lysis, or
chemotherapeutics and radiotherapy. In principal, therapeutically applicable targets may include CSC
surface markers, their distinct niches and microenvironments, or signaling cascades mediating stemness
or apoptosis of CSCs. While the suitability of surface markers for targeting CSCs is restricted in terms
of marker specificity, the NF-κB family and their signaling pathways mediating both self-renewal
and apoptosis of CScs may represent a promising target for therapeutic interventions. For instance,
the plant-derived agent triptolide, which is in a clinical phase II trial for treating rheumatoid arthritis,
was shown to downregulate NF-κB accompanied by reversed EMT and stemness features of pancreatic
CSCs as well as inhibition of tumor growth [162]. Accordingly, the amount of ovarian cancers stem
cells can also be reduced by blocking classical NF-κB signaling [108]. In this line, NF-κB target
genes may also be of interest for therapeutic applications, as genes like TERT were also shown to
be directly associated to CSC characteristics in GBM [73]. In addition, recently developed cellular
therapies like those utilizing genetically engineered T cells may circumvent limitations of current
treatment strategies [163] and be extended towards targeting CSCs in the future. Here, NF-κB c-Rel was
recently shown to be crucial for the Treg immune checkpoint in cancer with inhibition of c-Rel in Tregs
resulting in reduced melanoma growth and potentiated the effects of anti-PD-1 immunotherapy [164].
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As recently reviewed by Zhang and colleagues, normal stem cells can also act to target CSCs, since these
attract normal stem cells, resulting in reduced proliferation and metastasis [165]. As a summarizing
clinical perspective, mechanisms of NF-κB-inhibition targeting both CSC populations within the tumor
mass and maintenance of CSC characteristics may thus represent a promising strategy for novel
treatment schemes.
Author Contributions: Conceptualization, C.K. and B.K.; methodology, C.K.; writing—original draft preparation,
C.K.; writing—review and editing, C.B.-J.; T.B.; M.B.; C.F.; J.G.; E.H.; N.J.; F.M.; J.P.; M.S.; J.S.a.E.; T.V.; D.W.; F.W.;
L.W.; B.K.; visualization, J.G.; project administration, FBMB: B.K.; C.K.; J.S.a.E.; F.M.; funding acquisition, C.K. and
F.M.
Funding: This research received funding of the Bethel Foundation and the University of Bielefeld.
Acknowledgments: We thank Kaya Friedrich for help with Figure 3. Experiments involving human tissue
(e.g., Figure 3) involved patient’s informed consent and are ethically approved by the ethics commission of the
University of Münster, Germany, and the General Medical Council at Münster, Germany.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.;
Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID
mice. Nature 1994, 367, 645–648. [CrossRef]
2. Marsden, C.G.; Wright, M.J.; Pochampally, R.; Rowan, B.G. Breast tumor-initiating cells isolated from patient
core biopsies for study of hormone action. Methods Mol. Biol. 2009, 590, 363–375. [CrossRef]
3. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer
stem cell in human brain tumors. Cancer Res. 2003, 63, 5821–5828.
4. Di Tomaso, T.; Mazzoleni, S.; Wang, E.; Sovena, G.; Clavenna, D.; Franzin, A.; Mortini, P.; Ferrone, S.;
Doglioni, C.; Marincola, F.M.; et al. Immunobiological characterization of cancer stem cells isolated from
glioblastoma patients. Clin. Cancer Res. 2010, 16, 800–813. [CrossRef] [PubMed]
5. Caussinus, E.; Hirth, F. Asymmetric stem cell division in development and cancer. In Asymmetric Cell Division;
Progress in Molecular and Subcellular Biology; Springer: Berlin/Heidelberg, Germany, 2007; Volume 45,
pp. 205–225.
6. Mukherjee, S.; Kong, J.; Brat, D.J. Cancer stem cell division: When the rules of asymmetry are broken.
Stem Cells Dev. 2015, 24, 405–416. [CrossRef]
7. Yamamoto, M.; Taguchi, Y.; Ito-Kureha, T.; Semba, K.; Yamaguchi, N.; Inoue, J. NF-kappaB
non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype.
Nat. Commun. 2013, 4, 2299. [CrossRef]
8. Perkins, N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol.
Cell Biol. 2007, 8, 49–62. [CrossRef]
9. Kaltschmidt, B.; Kaltschmidt, C. NF-kappaB in the nervous system. Cold Spring Harb. Perspect. Biol. 2009,
1, a001271. [CrossRef]
10. Oeckinghaus, A.; Ghosh, S. The NF-kappaB family of transcription factors and its regulation. Cold Spring
Harb. Perspect. Biol. 2009, 1, a000034. [CrossRef] [PubMed]
11. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F.R.; Krahn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S.C.; et al.
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001,
293, 1495–1499. [CrossRef]
12. Xia, Y.; Shen, S.; Verma, I.M. NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2014, 2,
823–830. [CrossRef]
13. Hoesel, B.; Schmid, J.A. The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer
2013, 12, 86. [CrossRef]
14. Kaltschmidt, B.; Greiner, J.F.W.; Kadhim, H.M.; Kaltschmidt, C. Subunit-Specific Role of NF-kappaB in
Cancer. Biomedicines 2018, 6, 44. [CrossRef]
Cancers 2019, 11, 655 15 of 22
15. Riedlinger, T.; Haas, J.; Busch, J.; van de Sluis, B.; Kracht, M.; Schmitz, M.L. The Direct and Indirect Roles of
NF-kappaB in Cancer: Lessons from Oncogenic Fusion Proteins and Knock-in Mice. Biomedicines 2018, 6, 36.
[CrossRef]
16. Baud, V.; Collares, D. Post-Translational Modifications of RelB NF-kappaB Subunit and Associated Functions.
Cells 2016, 5, 22. [CrossRef]
17. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
18. Taniguchi, K.; Karin, M. NF-kappaB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol.
2018. [CrossRef]
19. Terzic, J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology 2010, 138,
2101–2114.e5. [CrossRef] [PubMed]
20. Lawrence, T.; Fong, C. The resolution of inflammation: Anti-inflammatory roles for NF-kappaB. Int. J.
Biochem. Cell Biol. 2010, 42, 519–523. [CrossRef] [PubMed]
21. Saccani, A.; Schioppa, T.; Porta, C.; Biswas, S.K.; Nebuloni, M.; Vago, L.; Bottazzi, B.; Colombo, M.P.;
Mantovani, A.; Sica, A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits
M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66, 11432–11440. [CrossRef]
[PubMed]
22. Long, H.; Xie, R.; Xiang, T.; Zhao, Z.; Lin, S.; Liang, Z.; Chen, Z.; Zhu, B. Autocrine CCL5 signaling
promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9
upregulation. Stem Cells 2012, 30, 2309–2319. [CrossRef]
23. Staudt, L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2010, 2, a000109. [CrossRef]
[PubMed]
24. Iliopoulos, D.; Hirsch, H.A.; Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA,
and IL6 links inflammation to cell transformation. Cell 2009, 139, 693–706. [CrossRef]
25. Ji, Z.; He, L.; Regev, A.; Struhl, K. Inflammatory regulatory network mediated by the joint action of NF-kB,
STAT3, and AP-1 factors is involved in many human cancers. Proc. Natl. Acad. Sci. USA 2019. [CrossRef]
[PubMed]
26. Markopoulos, G.S.; Roupakia, E.; Tokamani, M.; Alabasi, G.; Sandaltzopoulos, R.; Marcu, K.B.; Kolettas, E.
Roles of NF-kappaB Signaling in the Regulation of miRNAs Impacting on Inflammation in Cancer. Biomedicines
2018, 6, 40. [CrossRef]
27. Luningschror, P.; Stocker, B.; Kaltschmidt, B.; Kaltschmidt, C. miR-290 cluster modulates pluripotency by
repressing canonical NF-kappaB signaling. Stem Cells 2012, 30, 655–664. [CrossRef] [PubMed]
28. Luningschror, P.; Hauser, S.; Kaltschmidt, B.; Kaltschmidt, C. MicroRNAs in pluripotency, reprogramming
and cell fate induction. Biochim. Biophys. Acta 2013, 1833, 1894–1903. [CrossRef]
29. Qin, Q.; Xu, Y.; He, T.; Qin, C.; Xu, J. Normal and disease-related biological functions of Twist1 and underlying
molecular mechanisms. Cell Res. 2012, 22, 90–106. [CrossRef] [PubMed]
30. Min, C.; Eddy, S.F.; Sherr, D.H.; Sonenshein, G.E. NF-kappaB and epithelial to mesenchymal transition of
cancer. J. Cell. Biochem. 2008, 104, 733–744. [CrossRef]
31. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.;
Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell
2008, 133, 704–715. [CrossRef]
32. Huber, M.A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.;
Wirth, T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast
cancer progression. J. Clin. Investig. 2004, 114, 569–581. [CrossRef]
33. KEGG. NF-Kappa B Signaling Pathway—Homo Sapiens (Human). Available online: https://www.genome.
jp/kegg-bin/show_pathway?hsa04064 (accessed on 11 April 2019).
34. Kanehisa, M.; Sato, Y.; Furumichi, M.; Morishima, K.; Tanabe, M. New approach for understanding genome
variations in KEGG. Nucleic Acids Res. 2019, 47, D590–D595. [CrossRef]
35. Auphan, N.; DiDonato, J.A.; Rosette, C.; Helmberg, A.; Karin, M. Immunosuppression by glucocorticoids:
Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270, 286–290.
[CrossRef]
36. Ma, B.; Hottiger, M.O. Crosstalk between Wnt/beta-Catenin and NF-kappaB Signaling Pathway during
Inflammation. Front. Immunol. 2016, 7, 378. [CrossRef]
Cancers 2019, 11, 655 16 of 22
37. Schon, S.; Flierman, I.; Ofner, A.; Stahringer, A.; Holdt, L.M.; Kolligs, F.T.; Herbst, A. Beta-catenin regulates
NF-kappaB activity via TNFRSF19 in colorectal cancer cells. Int. J. Cancer 2014, 135, 1800–1811. [CrossRef]
38. Scheel, C.; Eaton, E.N.; Li, S.H.; Chaffer, C.L.; Reinhardt, F.; Kah, K.J.; Bell, G.; Guo, W.; Rubin, J.;
Richardson, A.L.; et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell
states in the breast. Cell 2011, 145, 926–940. [CrossRef] [PubMed]
39. Luo, K. Signaling Cross Talk between TGF-beta/Smad and Other Signaling Pathways. Cold Spring Harb.
Perspect. Biol. 2017, 9. [CrossRef]
40. Omuro, A.; DeAngelis, L.M. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013, 310,
1842–1850. [CrossRef]
41. Aldape, K.; Zadeh, G.; Mansouri, S.; Reifenberger, G.; von Deimling, A. Glioblastoma: Pathology, molecular
mechanisms and markers. Acta Neuropathol. 2015, 129, 829–848. [CrossRef] [PubMed]
42. Ellis, H.P.; Greenslade, M.; Powell, B.; Spiteri, I.; Sottoriva, A.; Kurian, K.M. Current Challenges in
Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.
Front. Oncol. 2015, 5, 251. [CrossRef] [PubMed]
43. Herrlinger, U.; Tzaridis, T.; Mack, F.; Steinbach, J.P.; Schlegel, U.; Sabel, M.; Hau, P.; Kortmann, R.D.;
Krex, D.; Grauer, O.; et al. Lomustine-temozolomide combination therapy versus standard temozolomide
therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09):
A randomised, open-label, phase 3 trial. Lancet 2019, 393, 678–688. [CrossRef]
44. Glas, M.; Rath, B.H.; Simon, M.; Reinartz, R.; Schramme, A.; Trageser, D.; Eisenreich, R.; Leinhaas, A.;
Keller, M.; Schildhaus, H.U.; et al. Residual tumor cells are unique cellular targets in glioblastoma. Ann.Neurol.
2010, 68, 264–269. [CrossRef] [PubMed]
45. Schneider, M.; Strobele, S.; Nonnenmacher, L.; Siegelin, M.D.; Tepper, M.; Stroh, S.; Hasslacher, S.;
Enzenmuller, S.; Strauss, G.; Baumann, B.; et al. A paired comparison between glioblastoma “stem
cells” and differentiated cells. Int. J. Cancer 2016, 138, 1709–1718. [CrossRef]
46. Bonavia, R.; Inda, M.M.; Cavenee, W.K.; Furnari, F.B. Heterogeneity maintenance in glioblastoma: A social
network. Cancer Res. 2011, 71, 4055–4060. [CrossRef] [PubMed]
47. Yan, K.; Yang, K.; Rich, J.N. The evolving landscape of glioblastoma stem cells. Curr. Opin. Neurol. 2013, 26,
701–707. [CrossRef] [PubMed]
48. Suva, M.L.; Rheinbay, E.; Gillespie, S.M.; Patel, A.P.; Wakimoto, H.; Rabkin, S.D.; Riggi, N.; Chi, A.S.;
Cahill, D.P.; Nahed, B.V.; et al. Reconstructing and reprogramming the tumor-propagating potential of
glioblastoma stem-like cells. Cell 2014, 157, 580–594. [CrossRef] [PubMed]
49. Seymour, T.; Nowak, A.; Kakulas, F. Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front. Oncol.
2015, 5, 159. [CrossRef]
50. Lathia, J.D.; Mack, S.C.; Mulkearns-Hubert, E.E.; Valentim, C.L.; Rich, J.N. Cancer stem cells in glioblastoma.
Genes Dev. 2015, 29, 1203–1217. [CrossRef] [PubMed]
51. Soubannier, V.; Stifani, S. NF-kappaB Signalling in Glioblastoma. Biomedicines 2017, 5, 29. [CrossRef]
52. Weller, M.; Butowski, N.; Tran, D.D.; Recht, L.D.; Lim, M.; Hirte, H.; Ashby, L.; Mechtler, L.; Goldlust, S.A.;
Iwamoto, F.; et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing
glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017, 18,
1373–1385. [CrossRef]
53. Zanca, C.; Villa, G.R.; Benitez, J.A.; Thorne, A.H.; Koga, T.; D’Antonio, M.; Ikegami, S.; Ma, J.; Boyer, A.D.;
Banisadr, A.; et al. Glioblastoma cellular cross-talk converges on NF-kappaB to attenuate EGFR inhibitor
sensitivity. Genes Dev. 2017, 31, 1212–1227. [CrossRef] [PubMed]
54. Wang, H.; Lathia, J.D.; Wu, Q.; Wang, J.; Li, Z.; Heddleston, J.M.; Eyler, C.E.; Elderbroom, J.; Gallagher, J.;
Schuschu, J.; et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.
Stem Cells 2009, 27, 2393–2404. [CrossRef] [PubMed]
55. Yang, W.; Xia, Y.; Cao, Y.; Zheng, Y.; Bu, W.; Zhang, L.; You, M.J.; Koh, M.Y.; Cote, G.; Aldape, K.; et al.
EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2
expression and promotes tumorigenesis. Mol. Cell 2012, 48, 771–784. [CrossRef] [PubMed]
56. Hjelmeland, A.B.; Wu, Q.; Wickman, S.; Eyler, C.; Heddleston, J.; Shi, Q.; Lathia, J.D.; Macswords, J.; Lee, J.;
McLendon, R.E.; et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010,
8, e1000319. [CrossRef] [PubMed]
Cancers 2019, 11, 655 17 of 22
57. Bredel, M.; Scholtens, D.M.; Yadav, A.K.; Alvarez, A.A.; Renfrow, J.J.; Chandler, J.P.; Yu, I.L.; Carro, M.S.;
Dai, F.; Tagge, M.J.; et al. NFKBIA deletion in glioblastomas. N. Engl. J. Med. 2011, 364, 627–637. [CrossRef]
[PubMed]
58. Happold, C.; Stojcheva, N.; Silginer, M.; Weiss, T.; Roth, P.; Reifenberger, G.; Weller, M. Transcriptional control
of O(6) -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma.
J. Neurochem. 2018, 144, 780–790. [CrossRef] [PubMed]
59. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.;
Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
60. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.;
Mason, W.; Mariani, L.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl.
J. Med. 2005, 352, 997–1003. [CrossRef] [PubMed]
61. Herrlinger, U.; Schafer, N.; Steinbach, J.P.; Weyerbrock, A.; Hau, P.; Goldbrunner, R.; Friedrich, F.; Rohde, V.;
Ringel, F.; Schlegel, U.; et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed
O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
J. Clin. Oncol. 2016, 34, 1611–1619. [CrossRef]
62. Kaus, A.; Widera, D.; Kassmer, S.; Peter, J.; Zaenker, K.; Kaltschmidt, C.; Kaltschmidt, B. Neural stem cells
adopt tumorigenic properties by constitutively activated NF-kappaB and subsequent VEGF up-regulation.
Stem Cells Dev. 2010, 19, 999–1015. [CrossRef]
63. Xie, T.X.; Xia, Z.; Zhang, N.; Gong, W.; Huang, S. Constitutive NF-kappaB activity regulates the expression
of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol. Rep. 2010, 23, 725–732.
64. Treps, L.; Perret, R.; Edmond, S.; Ricard, D.; Gavard, J. Glioblastoma stem-like cells secrete the pro-angiogenic
VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles 2017, 6, 1359479. [CrossRef]
65. Wick, W.; Gorlia, T.; Bendszus, M.; Taphoorn, M.; Sahm, F.; Harting, I.; Brandes, A.A.; Taal, W.; Domont, J.;
Idbaih, A.; et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N. Engl. J. Med. 2017, 377,
1954–1963. [CrossRef] [PubMed]
66. Da Hora, C.C.; Pinkham, K.; Carvalho, L.; Zinter, M.; Tabet, E.; Nakano, I.; Tannous, B.A.; Badr, C.E. Sustained
NF-kappaB-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a
vulnerability to EZH2 inhibition. Cell Death Discov. 2019, 5, 72. [CrossRef]
67. Tannous, B.A.; Badr, C.E. A TNF-NF-kappaB-STAT3 loop triggers resistance of glioma-stem-like cells to
Smac mimetics while sensitizing to EZH2 inhibitors. Cell Death Dis. 2019, 10, 268. [CrossRef]
68. Man, J.; Shoemake, J.; Zhou, W.; Fang, X.; Wu, Q.; Rizzo, A.; Prayson, R.; Bao, S.; Rich, J.N.; Yu, J.S. Sema3C
promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep. 2014, 9,
1812–1826. [CrossRef]
69. Rinkenbaugh, A.L.; Cogswell, P.C.; Calamini, B.; Dunn, D.E.; Persson, A.I.; Weiss, W.A.; Lo, D.C.; Baldwin, A.S.
IKK/NF-kappaB signaling contributes to glioblastoma stem cell maintenance. Oncotarget 2016, 7, 69173–69187.
[CrossRef] [PubMed]
70. Kim, S.H.; Ezhilarasan, R.; Phillips, E.; Gallego-Perez, D.; Sparks, A.; Taylor, D.; Ladner, K.; Furuta, T.;
Sabit, H.; Chhipa, R.; et al. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma
Stem Cells in an NF-kappaB-dependent Manner. Cancer Cell 2016, 29, 201–213. [CrossRef]
71. Simon, M.; Hosen, I.; Gousias, K.; Rachakonda, S.; Heidenreich, B.; Gessi, M.; Schramm, J.; Hemminki, K.;
Waha, A.; Kumar, R. TERT promoter mutations: A novel independent prognostic factor in primary
glioblastomas. Neuro-Oncology 2015, 17, 45–52. [CrossRef]
72. Reifenberger, G.; Wirsching, H.G.; Knobbe-Thomsen, C.B.; Weller, M. Advances in the molecular genetics of
gliomas—Implications for classification and therapy. Nat. Rev. Clin. Oncol. 2017, 14, 434–452. [CrossRef]
[PubMed]
73. Beck, S.; Jin, X.; Sohn, Y.W.; Kim, J.K.; Kim, S.H.; Yin, J.; Pian, X.; Kim, S.C.; Nam, D.H.; Choi, Y.J.; et al.
Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics
by inducing EGFR expression. Mol. Cells 2011, 31, 9–15. [CrossRef] [PubMed]
74. Barnes, B.; Kraywinkel, K.; Nowossadeck, E.; Schönfeld, I.; Starker, A.; Wienecke, A.; Wolf, U. Bericht zum
Krebsgeschehen in Deutschland 2016; Robert Koch-Institut: Berlin, Germany, 2016. [CrossRef]
Cancers 2019, 11, 655 18 of 22
75. Ostrom, Q.T.; Gittleman, H.; de Blank, P.M.; Finlay, J.L.; Gurney, J.G.; McKean-Cowdin, R.; Stearns, D.S.;
Wolff, J.E.; Liu, M.; Wolinsky, Y.; et al. American Brain Tumor Association Adolescent and Young Adult Primary
Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro-Oncology
2016, 18 (Suppl. 1), i1–i50. [CrossRef] [PubMed]
76. Vigneswaran, K.; Neill, S.; Hadjipanayis, C.G. Beyond the World Health Organization grading of infiltrating
gliomas: Advances in the molecular genetics of glioma classification. Ann. Transl. Med. 2015, 3, 95.
[CrossRef] [PubMed]
77. Jelsma, R.; Bucy, P.C. The treatment of glioblastoma multiforme of the brain. J. Neurosurg. 1967, 27, 388–400.
[CrossRef]
78. Weller, M.; Cloughesy, T.; Perry, J.R.; Wick, W. Standards of care for treatment of recurrent glioblastoma—Are
we there yet? Neuro-Oncology 2013, 15, 4–27. [CrossRef]
79. Huntly, B.J.; Gilliland, D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research.
Nat. Rev. Cancer 2005, 5, 311–321. [CrossRef]
80. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat. Med. 1997, 3, 730–737. [CrossRef]
81. Singh, S.K.; Clarke, I.D.; Hide, T.; Dirks, P.B. Cancer stem cells in nervous system tumors. Oncogene 2004, 23,
7267–7273. [CrossRef]
82. Abou-Antoun, T.J.; Hale, J.S.; Lathia, J.D.; Dombrowski, S.M. Brain Cancer Stem Cells in Adults and Children:
Cell Biology and Therapeutic Implications. Neurotherapeutics 2017, 14, 372–384. [CrossRef]
83. Hemmati, H.D.; Nakano, I.; Lazareff, J.A.; Masterman-Smith, M.; Geschwind, D.H.; Bronner-Fraser, M.;
Kornblum, H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003,
100, 15178–15183. [CrossRef]
84. Kunkle, B.; Yoo, C.; Roy, D. Discovering gene-environment interactions in glioblastoma through a
comprehensive data integration bioinformatics method. Neurotoxicology 2013, 35, 1–14. [CrossRef]
85. Parker, M.; Mohankumar, K.M.; Punchihewa, C.; Weinlich, R.; Dalton, J.D.; Li, Y.; Lee, R.; Tatevossian, R.G.;
Phoenix, T.N.; Thiruvenkatam, R.; et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in
ependymoma. Nature 2014, 506, 451–455. [CrossRef]
86. Pietsch, T.; Wohlers, I.; Goschzik, T.; Dreschmann, V.; Denkhaus, D.; Dorner, E.; Rahmann, S.; Klein-Hitpass, L.
Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation
of the NF-kappaB signaling pathway. Acta Neuropathol. 2014, 127, 609–611. [CrossRef]
87. Ozawa, T.; Arora, S.; Szulzewsky, F.; Juric-Sekhar, G.; Miyajima, Y.; Bolouri, H.; Yasui, Y.; Barber, J.; Kupp, R.;
Dalton, J.; et al. A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver
Functions in Addition to NF-kappaB. Cell Rep. 2018, 23, 3787–3797. [CrossRef]
88. Kaltschmidt, C.; Kaltschmidt, B.; Baeuerle, P.A. Stimulation of ionotropic glutamate receptors activates
transcription factor NF-kappa B in primary neurons. Proc. Natl. Acad. Sci. USA 1995, 92, 9618–9622.
[CrossRef] [PubMed]
89. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212–236. [CrossRef]
90. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin.
2011, 61, 69–90. [CrossRef]
91. Negri, E.; Franceschi, S.; Tzonou, A.; Booth, M.; La Vecchia, C.; Parazzini, F.; Beral, V.; Boyle, P.; Trichopoulos, D.
Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian
cancer. Int. J. Cancer 1991, 49, 50–56. [CrossRef]
92. Risch, H.A.; McLaughlin, J.R.; Cole, D.E.; Rosen, B.; Bradley, L.; Fan, I.; Tang, J.; Li, S.; Zhang, S.; Shaw, P.A.; et al.
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario,
Canada. J. Natl. Cancer Inst. 2006, 98, 1694–1706. [CrossRef] [PubMed]
93. Lynch, H.T.; Watson, P.; Lynch, J.F.; Conway, T.A.; Fili, M. Hereditary ovarian cancer. Heterogeneity in age at
onset. Cancer 1993, 71, 573–581. [CrossRef] [PubMed]
94. Harte, M.T.; Gorski, J.J.; Savage, K.I.; Purcell, J.W.; Barros, E.M.; Burn, P.M.; McFarlane, C.; Mullan, P.B.;
Kennedy, R.D.; Perkins, N.D.; et al. NF-kappaB is a critical mediator of BRCA1-induced chemoresistance.
Oncogene 2014, 33, 713–723. [CrossRef]
Cancers 2019, 11, 655 19 of 22
95. Volcic, M.; Karl, S.; Baumann, B.; Salles, D.; Daniel, P.; Fulda, S.; Wiesmuller, L. NF-kappaB regulates DNA
double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res. 2012, 40, 181–195.
[CrossRef]
96. Menon, U.; Skates, S.J.; Lewis, S.; Rosenthal, A.N.; Rufford, B.; Sibley, K.; Macdonald, N.; Dawnay, A.;
Jeyarajah, A.; Bast, R.C., Jr.; et al. Prospective study using the risk of ovarian cancer algorithm to screen for
ovarian cancer. J. Clin. Oncol. 2005, 23, 7919–7926. [CrossRef]
97. Bristow, R.E.; Tomacruz, R.S.; Armstrong, D.K.; Trimble, E.L.; Montz, F.J. Survival effect of maximal
cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis.
J. Clin. Oncol. 2002, 20, 1248–1259. [CrossRef]
98. Hacker, N.F.; Berek, J.S.; Lagasse, L.D.; Nieberg, R.K.; Elashoff, R.M. Primary cytoreductive surgery for
epithelial ovarian cancer. Obs. Gynecol. 1983, 61, 413–420.
99. Kehoe, S.; Hook, J.; Nankivell, M.; Jayson, G.C.; Kitchener, H.; Lopes, T.; Luesley, D.; Perren, T.; Bannoo, S.;
Mascarenhas, M.; et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced
ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet 2015, 386,
249–257. [CrossRef]
100. Bookman, M.A.; Brady, M.F.; McGuire, W.P.; Harper, P.G.; Alberts, D.S.; Friedlander, M.; Colombo, N.;
Fowler, J.M.; Argenta, P.A.; De Geest, K.; et al. Evaluation of new platinum-based treatment regimens in
advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 2009,
27, 1419–1425. [CrossRef]
101. Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.;
Beale, P.; Cervantes, A.; Kurzeder, C.; et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med.
2011, 365, 2484–2496. [CrossRef] [PubMed]
102. Zhou, N.; Wu, X.; Yang, B.; Yang, X.; Zhang, D.; Qing, G. Stem cell characteristics of dormant cells and
cisplatininduced effects on the stemness of epithelial ovarian cancer cells. Mol. Med. Rep. 2014, 10, 2495–2504.
[CrossRef] [PubMed]
103. Markowska, A.; Sajdak, S.; Huczynski, A.; Rehlis, S.; Markowska, J. Ovarian cancer stem cells: A target for
oncological therapy. Adv. Clin. Exp. Med. 2018, 27, 1017–1020. [CrossRef] [PubMed]
104. Parajuli, B.; Lee, H.G.; Kwon, S.H.; Cha, S.D.; Shin, S.J.; Lee, G.H.; Bae, I.; Cho, C.H. Salinomycin inhibits
Akt/NF-kappaB and induces apoptosis in cisplatin resistant ovarian cancer cells. Cancer Epidemiol. 2013, 37,
512–517. [CrossRef]
105. Hoogstad-van Evert, J.; Bekkers, R.; Ottevanger, N.; Schaap, N.; Hobo, W.; Jansen, J.H.; Massuger, L.;
Dolstra, H. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma
patients (a phase I study). Medicine 2019, 98, e14290. [CrossRef]
106. Tang, S.; Xiang, T.; Huang, S.; Zhou, J.; Wang, Z.; Xie, R.; Long, H.; Zhu, B. Ovarian cancer stem-like cells
differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling.
Cancer Lett. 2016, 376, 137–147. [CrossRef]
107. House, C.D.; Jordan, E.; Hernandez, L.; Ozaki, M.; James, J.M.; Kim, M.; Kruhlak, M.J.; Batchelor, E.;
Elloumi, F.; Cam, M.C.; et al. NFkappaB Promotes Ovarian Tumorigenesis via Classical Pathways That
Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH(+) Cancer Stem-like Cells.
Cancer Res. 2017, 77, 6927–6940. [CrossRef] [PubMed]
108. Gonzalez-Torres, C.; Gaytan-Cervantes, J.; Vazquez-Santillan, K.; Mandujano-Tinoco, E.A.;
Ceballos-Cancino, G.; Garcia-Venzor, A.; Zampedri, C.; Sanchez-Maldonado, P.; Mojica-Espinosa, R.;
Jimenez-Hernandez, L.E.; et al. NF-kappaB Participates in the Stem Cell Phenotype of Ovarian Cancer Cells.
Arch. Med. Res. 2017, 48, 343–351. [CrossRef]
109. Mikulasova, A.; Wardell, C.P.; Murison, A.; Boyle, E.M.; Jackson, G.H.; Smetana, J.; Kufova, Z.; Pour, L.;
Sandecka, V.; Almasi, M.; et al. The spectrum of somatic mutations in monoclonal gammopathy of
undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Haematologica 2017, 102, 1617–1625. [CrossRef]
110. Kortum, K.M.; Mai, E.K.; Hanafiah, N.H.; Shi, C.X.; Zhu, Y.X.; Bruins, L.; Barrio, S.; Jedlowski, P.; Merz, M.;
Xu, J.; et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and
Ras pathway genes. Blood 2016, 128, 1226–1233. [CrossRef]
Cancers 2019, 11, 655 20 of 22
111. Szczepek, A.J.; Bergsagel, P.L.; Axelsson, L.; Brown, C.B.; Belch, A.R.; Pilarski, L.M. CD34+ cells in the blood
of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene
rearrangements. Blood 1997, 89, 1824–1833.
112. Johnsen, H.E.; Bogsted, M.; Schmitz, A.; Bodker, J.S.; El-Galaly, T.C.; Johansen, P.; Valent, P.; Zojer, N.;
Van Valckenborgh, E.; Vanderkerken, K.; et al. The myeloma stem cell concept, revisited: From
phenomenology to operational terms. Haematologica 2016, 101, 1451–1459. [CrossRef]
113. Derudder, E.; Herzog, S.; Labi, V.; Yasuda, T.; Kochert, K.; Janz, M.; Villunger, A.; Schmidt-Supprian, M.;
Rajewsky, K. Canonical NF-kappaB signaling is uniquely required for the long-term persistence of functional
mature B cells. Proc. Natl. Acad. Sci. USA 2016, 113, 5065–5070. [CrossRef] [PubMed]
114. Sasaki, Y.; Derudder, E.; Hobeika, E.; Pelanda, R.; Reth, M.; Rajewsky, K.; Schmidt-Supprian, M. Canonical
NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell
proliferation upon activation. Immunity 2006, 24, 729–739. [CrossRef] [PubMed]
115. Hunter, J.E.; Leslie, J.; Perkins, N.D. c-Rel and its many roles in cancer: An old story with new twists.
Br. J. Cancer 2016, 114, 1–6. [CrossRef] [PubMed]
116. Hunter, J.E.; Butterworth, J.A.; Zhao, B.; Sellier, H.; Campbell, K.J.; Thomas, H.D.; Bacon, C.M.; Cockell, S.J.;
Gewurz, B.E.; Perkins, N.D. The NF-kappaB subunit c-Rel regulates Bach2 tumour suppressor expression in
B-cell lymphoma. Oncogene 2016, 35, 3476–3484. [CrossRef]
117. Schild, S.E.; Tan, A.D.; Wampfler, J.A.; Ross, H.J.; Yang, P.; Sloan, J.A. A new scoring system for predicting
survival in patients with non-small cell lung cancer. Cancer Med. 2015, 4, 1334–1343. [CrossRef] [PubMed]
118. Kim, C.F.; Jackson, E.L.; Woolfenden, A.E.; Lawrence, S.; Babar, I.; Vogel, S.; Crowley, D.; Bronson, R.T.;
Jacks, T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121, 823–835.
[CrossRef] [PubMed]
119. Berns, A. Stem cells for lung cancer? Cell 2005, 121, 811–813. [CrossRef]
120. Xu, X.; Rock, J.R.; Lu, Y.; Futtner, C.; Schwab, B.; Guinney, J.; Hogan, B.L.; Onaitis, M.W. Evidence for type II
cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2012, 109,
4910–4915. [CrossRef] [PubMed]
121. Hanna, J.M.; Onaitis, M.W. Cell of origin of lung cancer. J. Carcinog. 2013, 12, 6. [CrossRef]
122. Xu, X.; Huang, L.; Futtner, C.; Schwab, B.; Rampersad, R.R.; Lu, Y.; Sporn, T.A.; Hogan, B.L.; Onaitis, M.W.
The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. Genes Dev.
2014, 28, 1929–1939. [CrossRef] [PubMed]
123. Batra, S.; Balamayooran, G.; Sahoo, M.K. Nuclear factor-kappaB: A key regulator in health and disease of
lungs. Arch. Immunol. Ther. Exp. 2011, 59, 335–351. [CrossRef]
124. Chen, W.; Li, Z.; Bai, L.; Lin, Y. NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and
therapy target. Front. Biosci. (Landmark Ed.) 2011, 16, 1172–1185. [CrossRef]
125. Gu, L.; Wang, Z.; Zuo, J.; Li, H.; Zha, L. Prognostic significance of NF-kappaB expression in non-small cell
lung cancer: A meta-analysis. PLoS ONE 2018, 13, e0198223. [CrossRef]
126. Zhang, D.; Jin, X.; Wang, F.; Wang, S.; Deng, C.; Gao, Z.; Guo, C. Combined prognostic value of both RelA
and IkappaB-alpha expression in human non-small cell lung cancer. Ann. Surg. Oncol. 2007, 14, 3581–3592.
[CrossRef] [PubMed]
127. Qin, H.; Zhou, J.; Zhou, P.; Xu, J.; Tang, Z.; Ma, H.; Guo, F. Prognostic significance of RelB overexpression in
non-small cell lung cancer patients. Thorac. Cancer 2016, 7, 415–421. [CrossRef] [PubMed]
128. Zakaria, N.; Mohd Yusoff, N.; Zakaria, Z.; Widera, D.; Yahaya, B.H. Inhibition of NF-kappaB Signaling
Reduces the Stemness Characteristics of Lung Cancer Stem Cells. Front. Oncol. 2018, 8, 166. [CrossRef]
[PubMed]
129. WHO. Early Detection of Common Cancers—Colorectal Cancer. Available online: http://www.euro.who.int/
en/health-topics/noncommunicable-diseases/cancer/news/news/2012/2/early-detection-of-common-cancers/
colorectal-cancer (accessed on 7 March 2019).
130. Chan, A.T.; Giovannucci, E.L. Primary prevention of colorectal cancer. Gastroenterology 2010, 138,
2029–2043.e10. [CrossRef] [PubMed]
131. Ekbom, A.; Helmick, C.; Zack, M.; Adami, H.O. Ulcerative colitis and colorectal cancer. A population-based
study. N. Engl. J. Med. 1990, 323, 1228–1233. [CrossRef]
132. Ai, D.; Pan, H.; Han, R.; Li, X.; Liu, G.; Xia, L.C. Using Decision Tree Aggregation with Random Forest Model
to Identify Gut Microbes Associated with Colorectal Cancer. Genes 2019, 10, 112. [CrossRef] [PubMed]
Cancers 2019, 11, 655 21 of 22
133. Henne, K.; Schilling, H.; Stoneking, M.; Conrads, G.; Horz, H.P. Sex-specific differences in the occurrence of
Fusobacterium nucleatum subspecies and Fusobacterium periodonticum in the oral cavity. Oncotarget 2018,
9, 20631–20639. [CrossRef]
134. Delaney, C.P.; Lavery, I.C.; Brenner, A.; Hammel, J.; Senagore, A.J.; Noone, R.B.; Fazio, V.W. Preoperative
radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal
cancers. Ann. Surg. 2002, 236, 203–207. [CrossRef]
135. Kapiteijn, E.; Putter, H.; van de Velde, C.J. Cooperative Investigators of the Dutch ColoRectal Cancer Group.
Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal
cancer in The Netherlands. Br. J. Surg. 2002, 89, 1142–1149. [CrossRef] [PubMed]
136. Hohenberger, W.; Weber, K.; Matzel, K.; Papadopoulos, T.; Merkel, S. Standardized surgery for colonic cancer:
Complete mesocolic excision and central ligation–technical notes and outcome. Colorectal. Dis. 2009, 11,
354–364, discussion 364–355. [CrossRef]
137. Grothey, A.; Sobrero, A.F.; Shields, A.F.; Yoshino, T.; Paul, J.; Taieb, J.; Souglakos, J.; Shi, Q.; Kerr, R.;
Labianca, R.; et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N. Engl. J. Med. 2018,
378, 1177–1188. [CrossRef] [PubMed]
138. Wolpin, B.M.; Mayer, R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134, 1296–1310.
[CrossRef]
139. Sato, T.; Vries, R.G.; Snippert, H.J.; van de Wetering, M.; Barker, N.; Stange, D.E.; van Es, J.H.; Abo, A.;
Kujala, P.; Peters, P.J.; et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal
niche. Nature 2009, 459, 262–265. [CrossRef] [PubMed]
140. Vermeulen, L.; Todaro, M.; de Sousa Mello, F.; Sprick, M.R.; Kemper, K.; Perez Alea, M.; Richel, D.J.; Stassi, G.;
Medema, J.P. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.
Proc. Natl. Acad. Sci. USA 2008, 105, 13427–13432. [CrossRef] [PubMed]
141. Schwitalla, S.; Fingerle, A.A.; Cammareri, P.; Nebelsiek, T.; Goktuna, S.I.; Ziegler, P.K.; Canli, O.; Heijmans, J.;
Huels, D.J.; Moreaux, G.; et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of
stem-cell-like properties. Cell 2013, 152, 25–38. [CrossRef]
142. Roussos, E.T.; Keckesova, Z.; Haley, J.D.; Epstein, D.M.; Weinberg, R.A.; Condeelis, J.S. AACR special
conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010, 70,
7360–7364. [CrossRef]
143. Li, H.; Zhong, A.; Li, S.; Meng, X.; Wang, X.; Xu, F.; Lai, M. The integrated pathway of TGFbeta/Snail with
TNFalpha/NFkappaB may facilitate the tumor-stroma interaction in the EMT process and colorectal cancer
prognosis. Sci. Rep. 2017, 7, 4915. [CrossRef]
144. Kroepil, F.; Fluegen, G.; Totikov, Z.; Baldus, S.E.; Vay, C.; Schauer, M.; Topp, S.A.; Schulte am Esch, J.;
Knoefel, W.T.; Stoecklein, N.H. Down-regulation of CDH1 is associated with expression of SNAI1 in colorectal
adenomas. PLoS ONE 2012, 7, e46665. [CrossRef]
145. Min, J.; Liu, L.; Li, X.; Jiang, J.; Wang, J.; Zhang, B.; Cao, D.; Yu, D.; Tao, D.; Hu, J.; et al. Absence of DAB2IP
promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer. Sci. Rep.
2015, 5, 16578. [CrossRef]
146. Luo, J.L.; Maeda, S.; Hsu, L.C.; Yagita, H.; Karin, M. Inhibition of NF-kappaB in cancer cells converts
inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.
Cancer Cell 2004, 6, 297–305. [CrossRef] [PubMed]
147. Wang, D.; Fu, L.; Sun, H.; Guo, L.; DuBois, R.N. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell
Expansion and Metastasis in Mice. Gastroenterology 2015, 149, 1884–1895.e4. [CrossRef]
148. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [CrossRef]
[PubMed]
149. Schroder, F.H.; Hugosson, J.; Roobol, M.J.; Tammela, T.L.; Zappa, M.; Nelen, V.; Kwiatkowski, M.; Lujan, M.;
Maattanen, L.; Lilja, H.; et al. Screening and prostate cancer mortality: Results of the European Randomised
Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, 384, 2027–2035.
[CrossRef]
150. Bill-Axelson, A.; Holmberg, L.; Garmo, H.; Taari, K.; Busch, C.; Nordling, S.; Haggman, M.; Andersson, S.O.;
Andren, O.; Steineck, G.; et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year
Follow-up. N. Engl. J. Med. 2018, 379, 2319–2329. [CrossRef]
Cancers 2019, 11, 655 22 of 22
151. Wang, X.; Kruithof-de Julio, M.; Economides, K.D.; Walker, D.; Yu, H.; Halili, M.V.; Hu, Y.P.; Price, S.M.;
Abate-Shen, C.; Shen, M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature
2009, 461, 495–500. [CrossRef] [PubMed]
152. Rajasekhar, V.K.; Studer, L.; Gerald, W.; Socci, N.D.; Scher, H.I. Tumour-initiating stem-like cells in human
prostate cancer exhibit increased NF-kappaB signalling. Nat. Commun. 2011, 2, 162. [CrossRef]
153. Birnie, R.; Bryce, S.D.; Roome, C.; Dussupt, V.; Droop, A.; Lang, S.H.; Berry, P.A.; Hyde, C.F.; Lewis, J.L.;
Stower, M.J.; et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory
phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008, 9, R83. [CrossRef]
[PubMed]
154. Liu, L.; Li, E.; Luo, L.; Zhao, S.; Li, F.; Wang, J.; Luo, J.; Zhao, Z. PSCA regulates IL-6 expression through
p38/NF-kappaB signaling in prostate cancer. Prostate 2017, 77, 1389–1400. [CrossRef]
155. Lindner, L. Knochentumoren und Weichteilsarkome Empfehlungen zur Diagnostik, Therapie und Nachsorge;
Tumorzentrum München: Munic, Germany, 2017.
156. Dürr, H.R.; Tunn, P.U.; Schütte, J.; Hartmann, J.T.; Budach, V.; Werner, M. Seltene Knochentumoren der
Extremitäten. Onkologe 2009, 15, 277–291. [CrossRef]
157. Brown, H.K.; Tellez-Gabriel, M.; Heymann, D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017, 386,
189–195. [CrossRef]
158. Basu-Roy, U.; Seo, E.; Ramanathapuram, L.; Rapp, T.B.; Perry, J.A.; Orkin, S.H.; Mansukhani, A.; Basilico, C.
Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012, 31, 2270–2282.
[CrossRef] [PubMed]
159. Honoki, K.; Fujii, H.; Kubo, A.; Kido, A.; Mori, T.; Tanaka, Y.; Tsujiuchi, T. Possible involvement of stem-like
populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol. Rep. 2010, 24,
501–505. [CrossRef]
160. Slotta, C.; Schluter, T.; Ruiz-Perera, L.M.; Kadhim, H.M.; Tertel, T.; Henkel, E.; Hubner, W.; Greiner, J.F.W.;
Huser, T.; Kaltschmidt, B.; et al. CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound
defects of the cell cycle. PLoS ONE 2017, 12, e0182373. [CrossRef] [PubMed]
161. Slotta, C.; Storm, J.; Pfisterer, N.; Henkel, E.; Kleinwachter, S.; Pieper, M.; Ruiz-Perera, L.M.; Greiner, J.F.W.;
Kaltschmidt, B.; Kaltschmidt, C. IKK1/2 protect human cells from TNF-mediated RIPK1-dependent apoptosis
in an NF-kappaB-independent manner. Biochim. Biophys. Acta 2018. [CrossRef] [PubMed]
162. Liu, L.; Salnikov, A.V.; Bauer, N.; Aleksandrowicz, E.; Labsch, S.; Nwaeburu, C.; Mattern, J.; Gladkich, J.;
Schemmer, P.; Werner, J.; et al. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and
stem-like features in pancreatic cancer by NF-kappaB downregulation. Int. J. Cancer 2014, 134, 2489–2503.
[CrossRef] [PubMed]
163. Guedan, S.; Ruella, M.; June, C.H. Emerging Cellular Therapies for Cancer. Annu. Rev. Immunol. 2018.
[CrossRef] [PubMed]
164. Grinberg-Bleyer, Y.; Oh, H.; Desrichard, A.; Bhatt, D.M.; Caron, R.; Chan, T.A.; Schmid, R.M.; Klein, U.;
Hayden, M.S.; Ghosh, S. NF-kappaB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer.
Cell 2017, 170, 1096–1108.e13. [CrossRef]
165. Zhang, C.L.; Huang, T.; Wu, B.L.; He, W.X.; Liu, D. Stem cells in cancer therapy: Opportunities and challenges.
Oncotarget 2017, 8, 75756–75766. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
